{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:58:10Z","timestamp":1747184290557,"version":"3.40.5"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>After years of minimal innovation in pharmacotherapeutics, impressive outcomes in the treatment of opioid use disorder are being obtained from a new way of delivering an old medication; long\u2010acting injectable formulations of buprenorphine appear to produce compelling reductions in relapse to illicit opioid use not only during use but also following depot discontinuation. This commentary discusses potential mechanisms behind this observation, asks if the removal of the need for daily oral opioid agonist dosing furthers our understanding of addiction treatment and whether we should therefore consider expanding access to depot formulations.<\/jats:p>","DOI":"10.1111\/dar.13732","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T05:59:50Z","timestamp":1690869590000},"page":"261-264","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Does the advent of depot therapy represent a step change in our understanding of opioid use disorder and its treatment?"],"prefix":"10.1111","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4152-5570","authenticated-orcid":false,"given":"Emmert","family":"Roberts","sequence":"first","affiliation":[{"name":"National Addiction Centre Institute of Psychiatry, Psychology and Neuroscience, King's College London  London UK"},{"name":"Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine  Stanford California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Humphreys","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine  Stanford California USA"},{"name":"Veterans Affairs Palo Alto Health Care System  Menlo Park California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02252-2"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1081\/JA-120002807"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00095-0"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19121245"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.10.1303"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.23032"},{"key":"e_1_2_5_9_1","unstructured":"HumphreysK.Long\u2010acting medications for opioid addiction help patients control their future unreliable selves. Available from:https:\/\/www.statnews.com\/2017\/10\/19\/opioids-addiction-long-acting-medications\/"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001070"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.12.001"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320978102"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951508000254"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1191\/0269216306pm1125oa"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12333"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.06.007"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16171"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.13732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T11:48:20Z","timestamp":1706701700000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.13732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/dar.13732"],"URL":"https:\/\/doi.org\/10.1111\/dar.13732","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"type":"print","value":"0959-5236"},{"type":"electronic","value":"1465-3362"}],"subject":[],"published":{"date-parts":[[2023,7,31]]},"assertion":[{"value":"2023-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}